CCK or gastrin modulating benzo �b!�1,4! diazepines derivatives
    10.
    发明授权
    CCK or gastrin modulating benzo �b!�1,4! diazepines derivatives 失效
    CCK或胃泌素调节苯并[b] [1,4]二氮杂衍生物

    公开(公告)号:US5859007A

    公开(公告)日:1999-01-12

    申请号:US722051

    申请日:1996-11-14

    摘要: Benzo�b!�1,4!diazepine compounds of formula (I), where R.sup.1 is selected from C.sub.1 C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, phenyl, or substituted phenyl; R.sup.2 is selected from C.sub.3 -C.sub.6 alkyl, C.sub.3 C.sub.6 cycloalkyl, C.sub.3 -C.sub.6 alkenyl, benzyl, phenylC.sub.1 -C.sub.3 alkyl of substituted phenyl; or NR.sup.1 R.sup.2 together form 1,2,3,4-tetrahydroquinoline or benzazepine, mono-, di-, or trisubstituted independently with C.sub.1-6 alkyl C.sub.1-6 alkoxy or halogen substituents; p is an integer 0 or 1; q is an integer 0 or 1; r is an integer 0 or 1; t is an integer 0 or 1, provided that when r is 0 then t is 0; R.sup.3, R.sup.5, and R.sup.6 are independently hydrogen or C.sub.1-6 alkyl; R.sup.4 is C.sub.1-6 alkyl or C.sub.1-6 alkenyl; R.sup.7 is selected from the group consisting of hydrogen, C.sub.1-6 alkyl, C.sub.1-6 cycloalkyl, C.sub.1-6 alkenyl, phenyl, substituted phenyl, napthyl, heteroaryl, substituted heteroaryl, bicycloheteroaryl or substituted bicycloheteroaryl; or NR.sup.6 R.sup.7 together form a saturated 5,6, or 7 membered ring optionally interrupted by 1,2,3 or 4 N, S or O heteroatoms, with the proviso that any two O or S atoms are not bonded to each other, m is an integer selected from the group of 0, 1, 2, 3 or 4; R.sup.8 and R.sup.9 are selected from a variety of substituents; Z is hydrogen or halogen; novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).

    摘要翻译: PCT No.PCT / EP95 / 01336 Sec。 371日期:1996年11月14日 102(e)1996年11月14日PCT PCT 1995年4月13日PCT公布。 公开号WO95 / 28391 日期:1995年10月26日(I)式(I)的苯并[b] [1,4]二氮杂化合物,其中R 1选自C 1 -C 6烷基,C 3 -C 6环烷基,苯基或取代的苯基; R2选自C3-C6烷基,C3C6环烷基,C3-C6链烯基,苄基,取代苯基的苯基C1-3烷基; 或NR1R2一起形成1,2,3,4-四氢喹啉或苯并氮杂,独立地与C 1-6烷基C 1-6烷氧基或卤素取代基单取代,二取代或三取代; p是整数0或1; q是整数0或1; r为整数0或1; t为整数0或1,条件是当r为0时,t为0; R3,R5和R6独立地是氢或C1-6烷基; R4是C1-6烷基或C1-6链烯基; R 7选自氢,C 1-6烷基,C 1-6环烷基,C 1-6烯基,苯基,取代的苯基,萘基,杂芳基,取代的杂芳基,双环杂芳基或取代的双环杂芳基; 或NR6R7一起形成饱和的5,6或7元环,任选地被1,2,3或4个N,S或O杂原子间隔,条件是任何两个O或S原子彼此不结合,m是 选自0,1,2,3或4的整数; R8和R9选自多种取代基; Z是氢或卤素; 新型中间体,用于治疗肥胖的药物组合物,胆囊淤滞,胰腺分泌障碍,这种治疗方法和制备式(I)化合物的方法。